Business Context and Reporting Period
This Form 8-K is a current report filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on August 30, 2005. The report details unregistered sales of equity securities that occurred between August 1, 2005, and August 30, 2005.
Key Financial Metrics
- Shares Issued: 766,223 shares of common stock issued to 16 warrant holders.
- Gross Proceeds: $1,174,261 received from warrant exercises.
- Commission Obligation: Approximately $32,569 owed to Burnham Hill Partners (a division of Pali Capital, Inc.) representing a 4% cash commission on the exercises.
- Other Metrics: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the increase in outstanding common stock due to the exercise of warrants. The company received significant cash inflow from these exercises, offset slightly by the commission payment obligation. No other material changes to financial position are disclosed in this specific report.
Guidance, Outlook, and Risks
This filing contains no management guidance, future outlook, or discussion of general business risks. The transaction was executed in reliance upon Section 4(2) of the Securities Act of 1933, meaning the shares were not registered. The only contingency noted is the obligation to pay the 4% commission to the placement agent.
Investor Verification Checklist
- Verify the company name is AdventRX Pharmaceuticals, Inc., as the input metadata incorrectly listed Savara Inc.
- Confirm the total number of shares issued (766,223) and the gross proceeds ($1,174,261) match internal records.
- Ensure the $32,569 commission liability to Burnham Hill Partners is accounted for in the company's cash obligations.
- Validate that the exemption under Section 4(2) of the Securities Act of 1933 was properly applied for these unregistered sales.